Cancer Flashcards
cervical cancer epidemiology
younger women
peaks in reproductive years
cervical cancer pathology
squamous cell carcinoma (80%)
adenocarcinoma
cervical cancer aetiology
HPV (type 16 &18)
cervical cancer risk factors
increased risk of catching HPV
- early sexual activity
- increased number of sexual partners
- not using condoms
non-engagement with cervical screening smoking HIV COCP for >5 years Increased number of full-term pregnancies family history
cervical cancer presentation
may be asymptomatic abnormal vaginal bleeding vaginal discharge pelvic pain dyspareunia
abnormal appearance of cervix: ulceration, inflammation, bleeding, visible tumour
cervical intraepithelial neoplasia
grading system for level of dysphasia
CIN I: mild dysplasia, affecting ⅓ thickness of epithelial layer
CIN II: moderate dysplasia, affecting ⅔ thickness
CIN III: severe dysplasia (sometimes called cervical carcinoma in situ)
Cervical Screening
Look for precancerous changes (dysskaryosis)
every 3 years aged 25-49
every 5 years aged 50-64
cervical cancer investigation
Colposcopy
- Stains to differentiate abnormal areas (acetic acid, Schiller’s iodine test)
- Tissue sample (obtain through LLETZ or cone biopsy)
Staging of cervical cancer
1: confined to cervix
2: invades to uterus or upper ⅔ of vagina
3: invades pelvic wall or lower ⅓ of vagina
4: invades bladder, rectum or beyond pelvis
management of cervical cancer
CIN & Early-Stage 1: LLETZ or cone biopsy
Stage 1b-2A: radical hysterectomy & removal of local lymph nodes with chemo& radiotherapy
Stage 2B-4A: chemotherapy & radiotherapy
stage 4B: combination of surgery, radiotherapy, chemotherapy & palliative care
Benvacizumab (Avastin)
- monoclonal antibody can be used in combo with other chemo
- reduces development go new blood vessels
endometrial cancer
cancer of the endometrium: lining of uterus
endometrial cancer pathology
adenocarcinoma
oestrogen-dependent
endometrial hyperplasia
precancerous condition involving thickening of endometrium
types
- hyperplasia without atypic
- Atypical hyperplasia
Treatment
- intrauterine system (Mirena coil)
- Continuous oral progestogens
endometrial cancer risk factors
relate to patients exposure to unopposed oestrogen Increase age early onset of menstruation late menopause oestrogen only HRT no/fewer pregnancies Obesity PCOS Tamoxifen
Additional (not related to oestrogen)
T2DM
HNPCC or Lynch syndrome
Endometrial cancer protective factors
COCP
Mirena coil
increased pregnancies
smoking